Webinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST
Join us to learn about current trends in rare disease drug development and commercialization, as well as implications for rare disease product launches. In this webcast, we share learnings from our 125+ pharmaceutical product launches, insights to identify risk and strategies to mitigate them, and best practices for launch timelines and stage gates.
Rare disease products account for half of all US FDA approvals, most with fast-track designations, which means compressed launch timelines and increasingly competitive markets with smaller patient populations. Organizations need to start their project journey 24-36 months prior to approval to gain a comprehensive understanding of the patient journey, educate providers effectively, foster advocacy, and establish a clear path to diagnosis and access to treatment. Early alignment to a cross-functional strategy supports decisions about prioritizing and judiciously allocating limited resources pre-approval.
If you are developing assets for rare disease indications, take advantage of this presentation to learn how to ensure your launch is set up for success.
Key Learning Objectives:
Who Should Attend:
Kapil Raina, MD
Principal, Market Access
SVP, Commercial Strategy and Execution
Chris Zealey, MSc
Principal, Science and Strategy
Sixsense Strategy Group, a Herspiegel Company